Doctor Ophelia Qiping Yin
Daiichi Sankyo Pharma Development, Edison, New Jersey (United States of America)
Linking intrinsic factor X activity, a biologically relevant pharmacodynamic marker, to edoxaban plasma concentration and clinical outcomes in the ENGAGE AF-TIMI 48 trial
Event: ESC Congress 2016
Topic: Atrial fibrillation (AF)
Session: New trends in antithrombotic therapy for atrial fibrillation
ESC 365 is supported by
